8.1 Chronic Pain, Opioid Stewardship & SUD Management

Chronic Pain, Opioid Stewardship & SUD Management

Executive Summary: Chronic non-cancer pain management in ambulatory care requires a structured balance between functional restoration and harm mitigation. According to the 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain, non-pharmacological therapies and non-opioid medications represent the foundational first-line standard of care. When opioid analgesics are considered, the Board Certified Ambulatory Care Pharmacist (BCACP) must navigate multidimensional risk assessments, calculate Morphine Milligram Equivalents (MME), implement naloxone co-prescribing protocols, interpret complex urine drug screenings (UDT), manage adverse sequelae such as Opioid-Induced Constipation (OIC) with peripherally acting mu-opioid receptor antagonists (PAMORAs), execute safe opioid rotations, and manage Medications for Opioid Use Disorder (MOUD) including buprenorphine, methadone, and naltrexone.

1. 2022 CDC Clinical Practice Guideline & Multimodal Pain Assessment

The 2022 CDC Guideline updates recommendations for clinicians prescribing outpatient opioids for adults with acute, subacute, or chronic pain (excluding pain management related to sickle cell disease, cancer-related pain, palliative care, and end-of-life care).

Core Principles of Chronic Pain Care

1. Non-Opioid First-Line: Non-pharmacological therapies (exercise therapy, physical therapy, cognitive behavioral therapy [CBT], weight loss) and non-opioid pharmacotherapies (topical NSAIDs/capsaicin, oral NSAIDs, acetaminophen, SNRIs like duloxetine, gabapentinoids, TCAs) are preferred over opioids.
2. Functional Goal Setting: Establish realistic treatment goals for pain and function (e.g., ability to walk around the block, return to work) before initiating therapy. Opioids should only be continued if there is clinically meaningful improvement in both pain and physical function that outweighs risks.
3. Immediate-Release Formulation Selection: When initiating opioids for acute or chronic pain, clinicians should always start with immediate-release (IR) formulations rather than extended-release/long-acting (ER/LA) opioids.
4. Lowest Effective Dosage: Initiate at the lowest approved dosage and avoid escalating dosages without carefully reassessing the clinical justification and risk-benefit balance.

Validated Assessment & Risk Stratification Instruments

2. Urine Drug Testing (UDT): Immunoassay vs. Chromatography

Urine drug testing (UDT) is recommended prior to initiating chronic opioid therapy and at least annually (or more frequently based on risk stratification) to verify adherence, detect non-prescribed controlled substances, and identify undisclosed illicit drug use.

                                  URINE DRUG TESTING (UDT) WORKFLOW
                                  
                                   [ Point-of-Care Urine Specimen ]
                                                  │
                                                  ▼
                                  [ Step 1: Specimen Validity Check ]
                                  • Temperature (90°F - 100°F within 4 min)
                                  • Creatinine (>20 mg/dL), pH (4.5 - 8.9), Specific Gravity
                                                  │
                                                  ▼
                            [ Step 2: Presumptive Screening (Immunoassay) ]
                                                  │
                   ┌──────────────────────────────┴──────────────────────────────┐
                   ▼                                                             ▼
         [ Expected Result ]                                           [ Unexpected Result ]
         • Prescribed drug POSITIVE                                    • Prescribed drug NEGATIVE (non-adherent/diversion?)
         • Non-prescribed drug NEGATIVE                                • Non-prescribed drug POSITIVE (illicit/cross-react?)
                   │                                                             │
                   ▼                                                             ▼
         [ Continue Regimen ]                                  [ Step 3: Definitive Confirmatory Testing ]
                                                               • Order LC-MS / GC-MS (mass spectrometry)
                                                               • Quantifies exact molecules & specific metabolites
                                                               • Rules out immunoassay false positives

Presumptive Immunoassay vs. Definitive Confirmatory Testing

• Presumptive Screening (Immunoassays): Rapid, cost-effective point-of-care antibody-based tests. Detects broad drug classes (e.g., standard "Opiates" screen detects morphine and codeine). High risk of cross-reactivity and false negatives (e.g., synthetic opioids such as fentanyl, buprenorphine, methadone, and semisynthetics like oxycodone often do not trigger a standard opiate immunoassay unless specific targeted assays are ordered).
• Definitive Testing (GC-MS / LC-MS): Gas or Liquid Chromatography coupled with Mass Spectrometry. Highly sensitive and specific, separating and quantifying individual chemical compounds and metabolites (e.g., distinguishing morphine from hydromorphone or hydrocodone).

Common Immunoassay Cross-Reactivities & False Positives

Interpreting Opioid Metabolic Pathways

When analyzing confirmatory LC-MS reports, pharmacists must understand normal hepatic biotransformation pathways:

• Codeine $\rightarrow$ metabolizes via CYP2D6 to Morphine $\rightarrow$ metabolizes to Hydromorphone (minor).
• Hydrocodone $\rightarrow$ metabolizes via CYP2D6 to Hydromorphone (Dilaudid) and via CYP3A4 to Norhydrocodone.
• Oxycodone $\rightarrow$ metabolizes via CYP2D6 to Oxymorphone (Opana) and via CYP3A4 to Noroxycodone.
• Clinical Scenario: A patient prescribed oxycodone who tests positive for oxycodone and oxymorphone is demonstrating expected metabolic processing, not taking two separate opioid prescriptions.

3. Morphine Milligram Equivalents (MME) & Prescribing Precautions

Morphine Milligram Equivalents (MME) standardize the potency of various opioids relative to oral morphine (where oral morphine 1 mg = 1 MME) to assist in risk assessment.

Standard Equianalgesic Conversion Factors

4. Naloxone Co-Prescribing & Opioid Harm Mitigation

Naloxone is a pure competitive mu-opioid receptor antagonist that rapidly reverses life-threatening opioid-induced central nervous system and respiratory depression.

Clinical Indications for Co-Prescribing Naloxone

Under the 2022 CDC guidelines and state standing orders, pharmacists should proactively co-prescribe naloxone when any of the following risk factors are present:

1. High Daily Dosage: Cumulative opioid dosage ≥ 50 MME/day.
2. Concurrent Sedatives: Concurrent prescription of benzodiazepines, non-benzodiazepine GABA-A agonists (Z-drugs: zolpidem, eszopiclone), barbiturates, or muscle relaxants.
3. Substance Use History: Personal history of substance use disorder (SUD), alcohol use disorder, or prior non-fatal overdose.
4. Comorbid Respiratory or Organ Impairment: Chronic obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA), asthma, severe chronic kidney disease, or hepatic failure.
5. Household / Environmental Risk: Presence of children, adolescents, or individuals with SUD in the household.

Naloxone Outpatient Formulations & Administration Rules

Critical Pharmacokinetic Counseling Rule: The elimination half-life of naloxone is 30 to 90 minutes, whereas most oral opioids and transdermal patches have durations of action lasting 4 to 72 hours. Rebound respiratory depression can occur as naloxone wears off. Patients and caregivers must be instructed to call 911 immediately and administer a repeat naloxone dose every 2 to 3 minutes if the patient does not respond or relapses into respiratory depression.

5. Opioid-Induced Constipation (OIC) & PAMORA Pharmacotherapy

Opioid-Induced Constipation (OIC) results from the activation of peripheral mu-opioid receptors in the enteric nervous system (myenteric and submucosal plexuses), which inhibits peristalsis, delays gastric emptying, decreases intestinal secretions, and increases anal sphincter tone. Unlike opioid-induced nausea and sedation, patients do NOT develop tolerance to constipation.

Stepwise Management Hierarchy for OIC

1. Step 1 — Prophylactic Bowel Regimen (First-Line): Initiate a stimulant laxative (Senna 1–2 tablets daily to BID, or Bisacodyl 5–10 mg daily) with or without an osmotic laxative (Polyethylene Glycol [PEG 3350] 17 g daily in 8 oz water). Stool softeners (docusate) provide minimal efficacy as monotherapy ("all mush, no push"). Bulk-forming laxatives (psyllium, methylcellulose) are contraindicated without high fluid intake due to risk of fecal impaction and mechanical obstruction.
2. Step 2 — Targeted PAMORA Therapy (Refractory to Standard Laxatives): Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs) block gastrointestinal mu-receptors without crossing the intact blood-brain barrier, thereby normalizing bowel function without precipitating central opioid withdrawal or reversing analgesia.

PAMORA Comparative Pharmacology & Dosing

6. Opioid Rotation Mathematics & Cross-Tolerance Reduction

Opioid rotation is indicated for unmanageable adverse effects, inadequate analgesia despite dosage escalation, changes in clinical/renal/hepatic status, or formulary changes. Because patients exhibit incomplete cross-tolerance between different mu-opioid receptor ligands, failing to reduce the calculated equianalgesic dose can lead to fatal opioid overdose.

                                THE 5-STEP OPIOID ROTATION ALGORITHM
                                
    [ Step 1: Calculate Current 24-Hour Total Dose ]
    Sum all baseline scheduled and PRN doses consumed over 24 hours (mg/day).
                         │
                         ▼
    [ Step 2: Convert Current Opioid to 24-Hour Oral MME ]
    Multiply daily dose by the specific drug's equianalgesic conversion factor.
                         │
                         ▼
    [ Step 3: Convert Oral MME to Target Opioid Daily Dose ]
    Divide total 24-hour MME by the target opioid's conversion factor.
                         │
                         ▼
    [ Step 4: Apply Mandatory Incomplete Cross-Tolerance Reduction ]
    Reduce the calculated target 24-hour dose by 25% to 50%.
    • Use 50% reduction for elderly, frail, severe organ impairment, or switching to methadone.
    • Use 25% to 30% reduction if switching between standard opioids with uncontrolled pain.
                         │
                         ▼
    [ Step 5: Divide into Target Dosing Interval & Allocate Breakthrough Pain ]
    • Scheduled Regimen: Divide 24-hour reduced dose by frequency (e.g., q4h, q8h, q12h).
    • Breakthrough Dose: Prescribe short-acting formulation at 10% to 15% of the total 24-hour regimen q2-4h PRN.

Clinical Rotation Case Example

• Patient Profile: A 62-year-old patient with chronic back pain takes Oxycodone Extended-Release (OxyContin) 40 mg PO Q12H plus Oxycodone IR 10 mg PO TID PRN (uses all 3 doses daily). Due to insurance changes, the patient must rotate to Oral Morphine Sustained-Release (MS Contin).
• Step 1 (24-Hour Total Current Dose): $(40\text{ mg} \times 2) + (10\text{ mg} \times 3) = 80\text{ mg} + 30\text{ mg} = 110\text{ mg oral oxycodone/day}$.
• Step 2 (Convert to Baseline MME): $110\text{ mg oxycodone} \times 1.5 = \mathbf{165\text{ MME/day}}$.
• Step 3 (Convert to Target Opioid): Target is oral morphine (factor = 1.0) $\rightarrow 165\text{ mg oral morphine/day}$.
• Step 4 (Reduce for Cross-Tolerance): Apply a 30% reduction (due to stable pain control): $165\text{ mg} \times (1 - 0.30) = 115.5\text{ mg oral morphine/day} \approx 120\text{ mg/day}$.
• Step 5 (Scheduled & Breakthrough Regimen):
  • Scheduled MS Contin: $120\text{ mg/day} \div 2 = \mathbf{60\text{ mg PO Q12H}}$.
  • Breakthrough Morphine IR: $10\%\text{ to }15\%$ of $120\text{ mg} = 12\text{ to }18\text{ mg} \rightarrow \mathbf{15\text{ mg PO Q4H PRN}}$ breakthrough pain.

7. Medications for Opioid Use Disorder (MOUD / SUD Pharmacotherapy)

Pharmacotherapy is the evidence-based standard for Opioid Use Disorder (OUD), significantly reducing all-cause mortality, fatal overdose, transmission of infectious diseases, and criminal recidivism.

1. Buprenorphine / Naloxone (Suboxone, Zubsolv)

• Pharmacology: Buprenorphine is a partial mu-opioid receptor agonist (with high receptor binding affinity and slow dissociation rate) and a kappa-opioid receptor antagonist. The partial agonism provides a ceiling effect on respiratory depression, creating an exceptional safety profile.
• Precipitated Withdrawal Mechanism: Because buprenorphine possesses higher binding affinity than full agonists (e.g., oxycodone, morphine, heroin, fentanyl) but lower intrinsic efficacy, administering buprenorphine while full agonists occupy mu-receptors rapidly displaces full agonists, precipitating acute, severe withdrawal.
• Induction Rule: The patient must be in objective mild-to-moderate withdrawal prior to buprenorphine induction, verified by a Clinical Opiate Withdrawal Scale (COWS) score ≥ 8 to 12 (typically 12–24h after short-acting opioids, 24–48h after long-acting oral opioids, 48–72h+ after methadone/fentanyl).
• Role of the Naloxone Component: In Suboxone (4:1 buprenorphine:naloxone ratio), naloxone has negligible sublingual/oral bioavailability (<5%). If taken sublingually as prescribed, naloxone is inactive. However, if crushed and injected intravenously or snorted, naloxone becomes fully bioavailable and precipitates severe withdrawal, serving as an abuse-deterrent mechanism.
• Regulatory Modernization (The MAT Act): In December 2022, Congress passed the Mainstreaming Addiction Treatment (MAT) Act, eliminating the historical DEA "DATA 2000 X-Waiver". Any DEA-registered healthcare provider with Schedule III prescribing authority can now prescribe buprenorphine for OUD without patient-panel caps.

2. Methadone Maintenance Therapy

• Pharmacology: Full mu-opioid agonist, NMDA receptor antagonist, and weak inhibitor of serotonin/norepinephrine reuptake. Displays complex pharmacokinetics with a variable elimination half-life (15 to 60 hours, mean ~24–36h) that far exceeds its duration of analgesia (4–8h). Steady-state tissue accumulation occurs over 5 to 7 days, predisposing to delayed overdose toxicity during rapid upward titration.
• Safety & Monitoring: Dose-dependent QTc prolongation and Torsades de Pointes (obtain baseline ECG; monitor QTc especially at doses >100 mg/day or when combined with QTc-prolonging drugs). Extensively metabolized by CYP3A4 and CYP2B6 (interactions with azoles, HIV protease inhibitors, rifampin, efavirenz).
• Regulatory Framework (42 CFR Part 8): Methadone for the treatment of Opioid Use Disorder (OUD) can ONLY be dispensed through federally certified Opioid Treatment Programs (OTPs / methadone clinics) with directly observed daily dosing and strict take-home eligibility. Outpatient community pharmacies may only dispense methadone for the treatment of pain.

3. Extended-Release Naltrexone (Vivitrol)

• Pharmacology: Pure competitive opioid receptor antagonist (blocks mu, kappa, and delta receptors) with no agonist activity. Available as a monthly intramuscular gluteal depot injection (380 mg IM every 4 weeks) or oral tablet (50 mg daily).
• Mandatory Washout Window: Requires a strict 7- to 14-day opioid-free period (7–10 days for short-acting opioids, 14 days for buprenorphine or methadone) confirmed by negative UDT or a negative Naloxone Challenge Test (0.4–0.8 mg IV/SC). Administering naltrexone in an opioid-dependent patient precipitates immediate, severe, and prolonged withdrawal.
• Fatal Overdose Risk Upon Relapse: Naltrexone induces upregulation and resensitization of opioid receptors, leading to complete loss of opioid tolerance. If a patient discontinues naltrexone and resumes opioid use, previously tolerated opioid doses can cause fatal respiratory arrest.